|
|
Post by sayhey24 on Aug 4, 2024 16:28:22 GMT -5
Your post gave me goose bumps. LOL They wasted no time initiating this trial. Finally after 6 years. We are making progress. Who knows maybe we will get the afrezza/glp1 trial next or get to see the Inhale-2 results. |
|
|
|
Post by letitride on Aug 4, 2024 17:47:22 GMT -5
That was after one trial amazing what millions in revenue can do. Peds and gestational in progress the next 6 years is going to be awesome. Lets Go!
|
|
|
|
Post by prcgorman2 on Aug 4, 2024 20:15:04 GMT -5
LOL They wasted no time initiating this trial. Finally after 6 years. We are making progress. Who knows maybe we will get the afrezza/glp1 trial next or get to see the Inhale-2 results. Making progress? Yeah, I would say getting the Insulin Business Unit to be marginally profitable, running trials that are finally “moving the needle” for Afrezza, and simultaneously progressing the pipeline, and on the verge of debt free is indeed progress. And, considering a 1-2 year hiatus due to COVID, and recovering from a clofazimine production facility fire in Germany by quickly arranging to make it themselves is “progress”. If they actually manage to successfully bring both clofazimine and nintedanib to market, and dislodge Afrezza from the glacial pace of sales improvement (in a good way), I’m going to claim “epic” and not just progress. Lastly, the recent disastrous share price hit to Dexcom might actually motivate their CEO to partner in some way with MannKind either in a trial, or “repping” pilot. I feel sorry for the guy. My guess is the shareholders have come out with torches and pitchforks and they want blood. |
|
|
|
Post by agedhippie on Aug 4, 2024 22:18:13 GMT -5
Carol Levy is running the trial at the New York location (there are five locations.) The trial is scoped to the 2hr mark so the outcome is predictable.
|
|
|
|
Post by letitride on Aug 5, 2024 1:31:16 GMT -5
Outcome will be predictable with the trial data to prove its awesome. Lets Go!
|
|
|
|
Post by sayhey24 on Aug 5, 2024 8:56:01 GMT -5
Carol Levy is running the trial at the New York location (there are five locations.) The trial is scoped to the 2hr mark so the outcome is predictable. We like predictable. Thats the thing about afrezza it is so damn predictable. Lets hope they properly dose and if so afrezza will crush it. |
|
